Cargando…

Refractory pruritus responds to dupilumab in a patient with TTC7A mutation

Detalles Bibliográficos
Autores principales:	Alipour Tehrany, Yassaman, Marois, Louis, Colmant, Caroline, Marchand, Valérie, Kokta, Victor, Coulombe, Jérôme, Marcoux, Danielle, Haddad, Elie, McCuaig, Catherine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797900/ https://www.ncbi.nlm.nih.gov/pubmed/33457482 http://dx.doi.org/10.1016/j.jdcr.2020.12.004

Ejemplares similares

Argas reflexus dermatitis and nocturnal pruritus
por: Alipour Tehrany, Yassaman, et al.
Publicado: (2018)

Dupilumab for cancer-associated refractory pruritus
por: Talmon, Aviv, et al.
Publicado: (2023)

Chronic Pruritus Responding to Dupilumab—A Case Series
por: Zhai, Lisa L., et al.
Publicado: (2019)

Extramedullary hematopoiesis secondary to COVID-19: A first case report in a newborn
por: Caudrelier, Nicolas, et al.
Publicado: (2022)

Six cases of refractory pruritus and histologic dermal hypersensitivity reaction successfully treated with dupilumab
por: Edmonds, Nicole, et al.
Publicado: (2021)

Recalcitrant anal and genital pruritus treated with dupilumab()()()()
por: Yang, E.J., et al.
Publicado: (2018)

The use of dupilumab for the treatment of recalcitrant brachioradial pruritus
por: Abel, Mary Kathryn, et al.
Publicado: (2021)

Dupilumab Failure in Treating Dermatomyositis-Associated Pruritus
por: O'Brien, Margaret A, et al.
Publicado: (2022)

Baricitinib rapidly and sustainably relieves a patient from chronic pruritus of unknown origin refractory to dupilumab
por: Buttgereit, Thomas, et al.
Publicado: (2021)

Isotretinoin for the treatment of severe acneiform eruptions associated with the MEK inhibitor trametinib
por: Caruana, Marco, et al.
Publicado: (2020)

A successful case of dupilumab treatment for severe uremic pruritus
por: Silverberg, Jonathan I., et al.
Publicado: (2019)

Dupilumab Improves Pruritus in Netherton Syndrome: A Case Study
por: Inaba, Yutaka, et al.
Publicado: (2022)

A novel pathogenic RHOA variant in a patient with patterned cutaneous hypopigmentation associated with extracutaneous findings
por: Cai, Zhuo Ran, et al.
Publicado: (2022)

Hand dermatitis aggravated by contact allergy to methylisothiazolinone in protective nitrile gloves
por: André, Raphaël, et al.
Publicado: (2022)

Incidental improvement of programmed cell death-1 receptor inhibitor-induced vitiligo after initiation of dupilumab therapy for refractory pruritus
por: Robinson, Warner, et al.
Publicado: (2023)

Allergic contact dermatitis caused by octylisothiazolinone in a leather car seat: Case report and emergence of octylisothiazolinones in leather goods in Switzerland
por: Alipour Tehrany, Yassaman, et al.
Publicado: (2022)

Epidermolysis bullosa pruriginosa responding to dupilumab
por: Clawson, Rebecca C., et al.
Publicado: (2021)

Current TTC Systems and TTC-PON Upgrade
por: Brandao De Souza Mendes, Eduardo
Publicado: (2018)

Upadacitinib as a treatment for chronic pruritus secondary to polycythemia vera after failure with dupilumab
por: Wachuku, Christopher I., et al.
Publicado: (2023)

Subcutaneous nodules in children: Don’t forget deep granuloma annulare: A Case Report
por: Ran Cai, Zhuo, et al.
Publicado: (2020)

A Case of Tuberculous Granulomatous Panniculitis without Vasculitis
por: Tehrany, Yassaman Alipour, et al.
Publicado: (2015)

TTC PON
por: BARON, Sophie
Publicado: (2016)

TTC distribution
por: Taylor, B G
Publicado: (1995)

Aprepitant for the Treatment of Chronic Refractory Pruritus
por: He, Alice, et al.
Publicado: (2017)

Dupilumab induces a rapid decrease of pruritus in adolescents: A pilot real‐life study
por: Mastorino, Luca, et al.
Publicado: (2021)

Immunoglobulin G4-Related Disease-Associated Dermatitis with Pruritus: A Positive Response to Dupilumab
por: Beck, Tyler C., et al.
Publicado: (2023)

Chronic Pruritus in Atopic Patients Treated with Dupilumab: Real Life Response and Related Parameters in 354 Patients
por: Mastorino, Luca, et al.
Publicado: (2022)

Rapid resolution of widespread cutaneous lichen planus and generalized pruritus in an elderly patient following treatment with dupilumab
por: Kazemi, Soroush, et al.
Publicado: (2022)

Treatment for Refractory Pruritus Using Oral Aprepitant
por: Huh, Joon Won, et al.
Publicado: (2016)

Multiple Intestinal Atresia With Combined Immune Deficiency Related to TTC7A Defect Is a Multiorgan Pathology: Study of a French-Canadian-Based Cohort
por: Fernandez, Isabel, et al.
Publicado: (2014)

Status of the TTC upgrade
por: Baron, S, et al.
Publicado: (2007)

TTC Upgrade Plans
por: Mrs. BARON, Sophie
Publicado: (2014)

Pelvic congestion syndrome
por: Robertson, Meiri, et al.
Publicado: (2015)

Immunostimulating Commensal Bacteria and Their Potential Use as Therapeutics
por: McCuaig, Bonita, et al.
Publicado: (2023)

Topical treatment of dupilumab-associated refractory conjunctivitis and keratitis
por: Di Staso, Federico, et al.
Publicado: (2022)

Dupilumab and tezepelumab in severe refractory asthma: new opportunities
por: Ragnoli, Beatrice, et al.
Publicado: (2022)

Refractory Pediatric Fibrostenotic Eosinophilic Esophagitis Treated With Dupilumab
por: Gangadharan Nambiar, Gopinathan, et al.
Publicado: (2022)

Effect of Dupilumab on Generalized Verrucosis in Refractory Bullous Pemphigoid
por: WANG, Qijun, et al.
Publicado: (2023)

Plasmapheresis for Refractory Pruritus due to Drug-Induced Cholestasis
por: Al-Azzawi, Hasan, et al.
Publicado: (2017)

Modules development for the TTC system
por: Gällnö, P
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_bofnri6u53p8o94bpdgbojmr1s